Skip to main content
SpringerLink
Log in

Increasing evidence that the risks of rhAPC may outweigh its benefits

  • Editorial
  • Published:
Intensive Care Medicine Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

References

  1. Kanji S, Perreault MM, Chant C, Williamson D, Burry L (2007) Evaluating the use of Drotrecogin alfa (activated) in adult severe sepsis: a Canadian multicenter observation study. Intensive Care Med DOI 10.1007/s00134-007-0555-9

  2. Bertolini G, Rossi C, Anghileri A, Livigni S, Addis A, Poole D (2007) Use of drotrecogin alfa (activated) in Italian intensive care units. The results of a nationwide survey. Intensive Care Med DOI 10.1007/s00134-007-0554-x

  3. Steingrub J, Sanchez P, Zeckel M, Bates B, Qualy R (2003) Safety of drotrecogin alfa (activated): results of MERCURY, a retrospective multicenter observation study. Crit Care Med 31:A117

    Google Scholar 

  4. Tanzi M (2004) Use of drotrecogin alfa (activated) (Xigris) for the treatment of severe sepsis: medical use evaluation by Novation, the supply company of VHA and UHC. Novation

  5. Deans KJ, Minneci PC, Banks SM, Natanson C, Eichacker PQ (2004) Substantiating the concerns about recombinant human activated protein C use in sepsis. Crit Care Med 32:2542–2543

    Article  PubMed  Google Scholar 

  6. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopex-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW et al. (2001) Efficacy and safety of human activated protein C for severe sepsis. N Engl J Med 344:699–709

    Article  PubMed  CAS  Google Scholar 

  7. Abraham E, Laterre F, Garg R et al. (2005) Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 353:1332–1341

    Article  PubMed  CAS  Google Scholar 

  8. Eisenberg P. Discontinuation of study F1K-MC-EVBP, investigation of the efficacy and safety of Drotrecogin alfa (activated) in pediatric severe sepsis (letter). http://www.fda.gov/medwatch/SAFETY/2005/xigris_dearhcp_4-21-05.htm. Accessed 5 July 2005

  9. Eichacker PQ, Natanson C (2003) Recombinant human activated protein C in sepsis: inconsistent trial results, an unclear mechanism of action, and safety concerns resulted in labeling restrictions and the need for phase IV trials. Crit Care Med 31:S94–S96

    Article  PubMed  CAS  Google Scholar 

  10. Eisenberg P. Important Drug Warning (letter) http://www.fda.gov/medwatch/SAFETY/2005/xigris_DHCP.htm. Accessed 5 July 2005

  11. Vincent JL, Bernard GR, Beale R, Doig C, Putenson C, Dhainaut JF, Artigas A, Fumagelli R, Macias W, Wright T, Wong K, Sundin DP, Turlo MA, Janes J, for the ENHANCE Study Group (2005) Drotrecogin alfa (activated) treatment in severe sepsis from the Global Open-label Trial ENHANCE: further evidence for survival and safety. Crit Care Med 33:2266–2277

    Article  PubMed  CAS  Google Scholar 

  12. Eichacker PQ, Danner RL, Suffredini AF, Cui X, Natanson C (2005) Reassessing recombinant human activated protein C for sepsis: time for a new randomized trial. Crit Care Med 33:2426–2428

    Article  PubMed  Google Scholar 

  13. Hunter D (2006) First gather the data. N Engl J Med 354:329–331

    Article  PubMed  CAS  Google Scholar 

  14. Vlahakes GJ (2006) The value of phase 4 clinical testing. N Engl J Med 354:413–415

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Critical Care Medicine, Building 10, Room 7D43, Clinical Center, National Institutes of Health, MD 20892, Bethesda, USA

    Peter Q. Eichacker & Charles Natanson

Authors
  1. Peter Q. Eichacker
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Charles Natanson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Peter Q. Eichacker.

Additional information

This editorial refers to the articles available at: http://dx.doi.org/10.1007/s00134-007-0554-x and http://dx.doi.org/10.1007/s00134-007-0555-9

Rights and permissions

Reprints and permissions

About this article

Cite this article

Eichacker, P.Q., Natanson, C. Increasing evidence that the risks of rhAPC may outweigh its benefits. Intensive Care Med 33, 396–399 (2007). https://doi.org/10.1007/s00134-007-0556-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00134-007-0556-8

Search

Navigation